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Abstract 
A series of novel bis-tetrahydropyran 1,4-triazole analogues based on the acetogenin 
framework display low micromolar trypanocidal activities towards both bloodstream 
and insect forms of Trypanosoma brucei, the causative agent of African sleeping 
sickness. A divergent synthetic strategy was adopted for the synthesis of the key 
tetrahydropyran intermediates to enable rapid access to diastereochemical variation 
either side of the 1,4-triazole core. The resulting diastereomeric analogues displayed 
varying degrees of trypanocidal activity and selectivity in structure activity 
relationship studies. 
 
Introduction 
Neglected tropical diseases are a continuing health concern in developing countries 
due to the lack of effective prevention methods and therapeutic agents.[1] One of these 
prevalent Neglected tropical diseases which has been slowly attracting attention over 
the past few years is African sleeping sickness or Human African Trypanosomiasis 
(HAT), caused by the protozoan parasite Trypanosoma brucei that is transmitted by 
the bite of the Tsetse fly. HAT is a major health concern in sub-Saharan Africa 
threatening more than 60 million people. The annual mortality rate of HAT estimated 
by the World Health Organization (WHO) stands at approximately 8000 with less 
than 30,000 new cases per year based on recent reported cases.[2] At present the 
treatment for HAT is extremely limited and dependent upon the disease stage of HAT 
infection i.e. the lymphatic first stage or the second neurological stage when the T. 
brucei parasite has crossed the blood brain barrier. Four drugs are used in the 
treatment of HAT (Figure 1), namely suramin (1) and pentamidine (2) for stage one 
HAT and melarsoprol (3) and eflornithine (4) for stage two. These drugs are difficult 
to administer to patients often requiring lengthy infusion rates, have varying degrees 
of human toxicity and resistance is becoming a significant problem.[3] In an effort to 
reduce the costs associated with these drugs, improve the logistics of their 
administration and reduce drug resistance (a common problem associated with 
parasitic diseases), a nifurtimox-eflornithine combination therapy (NECT, nifurtimox 
5 is used clinically to treat Chagas disease) has been recently introduced for stage 2 
HAT by the WHO.[4] This combination therapy maintains the efficacy of eflornithine 
at lower dosages, while reducing the toxic side effects associated with eflornithine 
monotherapy. Despite the success of NECT, there is a lack of new effective 
therapeutic agents and the onset drug resistance remains a serious threat to current 
therapies,[5] highlighting the urgent demand for the development of new drug-like 
molecules and their clinical implementation as effective HAT therapies. 
 
[INSERT FIGURE 1] 
 
The acetogenins are a class of polyketide natural products isolated from the 
annonaceae plant species found in the tropical regions of West Africa and South 
America.[6,7] Chamuvarinin (6) was isolated in 2004 by Laurens et. al. from the roots 
of the bush banana plant Uvaria chamae and showed significant cytotoxicity against 
the KB 3-1 cervix cancer cell line (IC50 value of 0.8 nM), shown in Figure 2.[8] In 
2011 we reported the total synthesis of chamuvarinin, we showed that 6 and a series 
of synthetic derivatives exhibited low micromolar activities towards both the 
bloodstream and procyclic forms of T. brucei.[9] These encouraging preliminary 
results and the limited investigations into trypanocidal activity of the acetogenins[10] 
prompted our initial interest in designing simplified analogues of 6 which retain the 
important structural features of the acetogenin family of natural products. In an effort 
to reduce structural complexity it was hypothesized that a 1,4-triazole motif could 
form an effective spatial mimic of the central C20-C23 tetrahydrofuran (THF) motif 
found in chamuvarinin (6). The synthesis and incorporation of THF motifs are 
notoriously difficult hence, the C16-19 THF ring system of 6 was substituted with the 
readily accessible and manageable tetrahydropyran (THP) motif, 7, Figure 2. The 
heterocyclic spacer was envisioned to arise from the “click” reaction of two THP 
subunits, whilst the butenolide moiety could be appended to the ether core in an 
analogous manner to 6 by a suitable length alkyl spacer. 
 
[INSERT FIGURE 2] 
Results and Discussion 
 
Chemistry 
As outlined in Scheme 1, intermediate THP alcohols 8a and 9a could be readily 
assembled in three steps from (S)-epoxyoctane (10a)[11] via Cu(I)-promoted ring 
opening of 10a with homoallyl magnesium bromide followed by m-CPBA 
epoxidation and subsequent in situ acid mediated ring closure to provide a readily 
separable mixture of diastereomeric alcohols 8a and 9a. This divergent approach 
provided an excellent opportunity to introduce structural variation within the THP 
scaffolds. With the alcohols in hand, both diastereomers could be independently 
converted to the azide by Mitsunobu reaction (DPPA, DIAD, iPr2NEt, PPh3) of 
alcohols 8a and 9a to give 11a and 12.[12] The enantiomeric syn azide (13) could be 
accessed in an analogous manner from (R)-epoxyoctane.[11] For the alkyne subunits, 
syn-8a and anti-9a alcohols were oxidized under Swern conditions to afford 
aldehydes 14a and 15a in excellent yields and subsequent exposure of 14a to Ohira-
Bestmann homologation[13] gave exclusively syn-16a in 72% yield. Due to 
epimerization of aldehyde 15a under the mildly basic conditions an alternative two-
step Corey-Fuchs homologation[14] approach was adopted, giving 17a in 70% yield. 
The incorporation of terminal oxygenation as a functional handle for extended 
elaboration was achieved by synthesis of the corresponding benzylated and silylated 
series of azides 11b-c and alkynes 16b and 17b from epoxides 10b and 10c. 
 
[INSERT Scheme 1] 
 
The central 1,4-triazole scaffold was conveniently installed by application of the 
Cu(I) catalyzed Huisgen 1,3-dipolar cycloaddition (Scheme 2).[15] Thus, 
diastereomeric analogues of the alkyl, benzylated and silylated bis-THP triazole 
motifs were synthesized by treatment of the corresponding azides 11a-c, 12, 13 and 
alkynes 16a-b, 17a-b under “click” reaction conditions (CuSO4, Na ascorbate) to 
afford triazole products 18a-d, 19a-b, 20a-b, 21a-b and 22 in good yields. 
 
[INSERT Scheme 2] 
 
Benzylated 18b-c, 19b, 20b, 21b and 22 analogues, outlined in Scheme 3, were 
deprotected under atmospheric hydrogenolysis (20% Pd(OH)2/C, H2) to the 
corresponding alcohols 23-28 (entries 1-6) in excellent yields. 
 
[INSERT Scheme 3] 
Table in Scheme to be below Scheme 3 – both original and revised submitted 
Entry Triazole Product Yield (%) 
1 18b: R1 = Et, R2 = OBn 23: R1 = Et, R2 = OH 92 
2 19b: R1 = Et, R2 = OBn 24: R1 = Et, R2 = OH 95 
3 21b: R1 = Et, R2 = OBn 25: R1 = Et, R2 = OH 93 
4 22: R1 = Et, R2 = OBn 26: R1 = Et, R2 = OH 92 
5 22: R1 = Et, R2 = OBn 27: R1 = Et, R2 = OH 90 
6 18c: R1 = OBn, R2 = Et 28: R1 = OH, R2 = Et 100 
 
 
Having previously established SAR data for the advanced analogues of chamuvarinin, 
it was observed that incorporation of the butenolide side chain impacted positively on 
the trypanocidal activity. Thus, installation of the butenolide motif to successfully 
mimic chamuvarinin was accomplished in four steps from lead alcohol 23, outlined in 
Scheme 4. Alcohol 23 was manipulated to sulfone 29 via a two-step Mitsunobu 
reaction and catalytic Mo[VI][7] oxidation protocol.[16] Subsequent Julia-Kocienski 
olefination[16] with aldehyde 30[9,18] and diimide reduction[19] (TsNHNH2, NaOAc) 
provided advanced analogue 31. To ascertain whether the triazole analogue would 
bind in a directional manner to the unknown protein target, analogue 32 was prepared 
in an analogous manner to 31 from alcohol 28 via sulfone 33. 
 
[INSERT Scheme 4] 
 
Having successfully installed the butenolide motif and in an effort to further extend 
the SAR data, bis-directional analogue 34, outlined in Scheme 5, was synthesized in 
six steps from advanced triazole 18d. Silyl deprotection of 18d to alcohol 35, 
followed by a Mitsunobu/oxidation protocol gave sulfone 36. Julia-Kocienski 
olefination of sulfone 36 with 30 and subsequent diimide reduction gave triazole 37. 
Benzyl deprotection of 37 with boron trichloride furnished alcohol 34 in 23% yield. 
Diol analogue 38 was accessed in excellent yield from alcohol 35 under atmospheric 
hydrogenolysis. 
 
[INSERT Scheme 5] 
 
Structure-activity relationship summary 
 
The primary mode of action for acetogenins in mammalian cells is inhibition 
of Complex I of the mitochondrial electron transport chain (ETC).[20] In contrast, 
bloodstream (BSF) T. brucei lacks functional Complexes I, III and IV and instead 
relies on alternative oxidases (TAO, AOX2) to enable mitochondrial respiration, 
while the procyclic (Pro) form expresses both a fully functional ETC and the 
alternative oxidases.[21] Thus in order to assess whether the triazole based analogues 
share a common mitochondrial target and identify key structural features required for 
parasitic inhibition screening against the bloodstream and procyclic forms of T. brucei 
and the mammalian HeLa cell line,[22] was performed (Table 1). From the data it was 
evident that the stereochemistry surrounding the THP ring systems and the 
functionalization of the terminal motifs impacted on the T. brucei inhibition profile. 
In comparison to chamuvarinin (6), the initial set of diastereomeric alkyl triazoles 
20a, 21a and 18a (entries 1, 4, 7) were >17 times less potent than 6 and indicated that 
stereochemistry had little effect on the inhibition profile. Surprisingly analogue 19a 
(entry 12) displayed good levels of T. brucei inhibition with an EC50 value of 7.6 ± 
0.3 µM and moderate levels of parasite selectivity (SI = 21.9). Introduction of 
terminal oxygenation as a handle for further manipulation to one side of the alkyl side 
chain, analogues 21b, 18b, 19b and 22 (entries 5, 8, 13, 15), resulted in good 
micromolar activities with EC50 values <10 µM. Interestingly, the anti-anti analogue 
20b (entry 2) was devoid of HeLa and T. brucei activity. By comparison, analogue 
21b (entry 5) displayed good levels of parasite inhibition and selectivity with an SI of 
23. For analogues 24 and 27 (entries 14 and 16), removal of the benzyl group resulted 
in ~2-fold loss in parasite activity. Removal of the benzyl group from analogue 21b 
(entry 5) to give 26 (entry 6) led to a significant loss in parasitic activity and 
selectivity, EC50 values of 3.1 ± 0.1 and 72.4 ± 3.9 µM and SI’s of 23 and 0.8, 
respectively. The anti-anti analogue 25 (entry 3) was still devoid of parasitic activity, 
despite transformation to the free hydroxyl.  Gratifyingly, introducing the free 
hydroxyl to analogue 23 (entry 9) led to a slight increase in T. brucei inhibition and 
23 has shown comparable levels of parasitic activity to that of chamuvarinin (6), EC50 
values of 1.80 ± 0.10 and 1.4 ± 0.1 µM, respectively. On the basis of 23, the bis-
directional analogue 35 (entry 10) was tested in the hope of further improving the 
activity. Unfortunately, 35 was 9 times less potent than 23 and subsequent removal of 
the benzyl group to give diol 38 (entry 11) resulted in significantly diminished 
activities. Comparison of the biological data for the ethyl, benzyl and alcohol triazole 
series, implies that the benzyl group may be potentially interacting with residues at a 
protein target site, which an alcohol group cannot accommodate. Alternatively, or as 
well as the benzyl group may be able to readily insert itself into the lipophilic 
membrane, whereas the hydrophilic alcohol incurs a greater penalty for membrane 
insertion. 
 
[Insert Table 1 – double column width – appended at end of manuscript] 
Caption for Table 1 
Table 1. SAR data for ethyl analogues 20a, 21a, 18a, 19a, benzyl analogues 20b, 21b, 
18b, 35, 19b, 22 and alcohol analogues 23-27, 38; selectivity index refers to BSF 
parasitic inhibition versus mammalian HeLa inhibition; chamuvarinin (6, T. brucei 
(BSF) EC50 = 1.4 ± 0.1 µM; T. brucei (Pro) EC50 = 1.9 ± 0.1 µM; HeLa EC50 = 2.9 ± 
0.7 µM taken from ref. 9). 
 
The synthesis of triazole analogues with terminal oxygenation has provided a 
functional handle for further elaboration (Table 2). The non-natural chamuvarinin-like 
analogues previously reported revealed that introduction of the butenolide side chain 
resulted in a >5-fold increase in T. brucei activity. Encouraged by the potent activity 
of lead alcohol 23 (entry 1), it was decided to incorporate the butenolide moiety based 
on this structure. Analogues 31 and 32 (entries 2 and 3) clearly highlight the 
importance of the spatial orientation of the pendent butenolide sidechain. While 31 
was essentially inactive, 32 displayed low micromolar selective activities against both 
forms of T. brucei with EC50 values of 3.2 ± 0.1 and 5.7 ± 0.6 µM respectively and a 
selectivity index of 15.8. This suggests that although the structures are only subtly 
different at face value, their binding/interaction is highly specific and indicative of a 
protein target, rather than the biophysical properties of the compounds. 
 
[Insert Table 2] – Figure containing structures to be inserted above table 2  
Caption for Table 2 
Table 2. Biological profiles for analogues 23, 31-32, 34 and 37, selectivity index 
refers to BSF parasitic inhibition versus mammalian HeLa inhibition. 
 
Entry Analogue T. brucei (BSF)   
EC50 (µM) 
T. brucei (Pro)  
EC50  (µM) 
HeLa 
EC50 (µM) 
Selectivity 
Index 
1 23 1.8 ± 0.1 0.8 ± 0.11 7.0 ± 1.0 3.9 
2 31 >500 >1000 >1000 - 
3 32 3.2 ± 0.1 5.7 ± 0.6 50.8 ± 3.7 15.8 
4 37 5.2 ± 0.3 19.2 ± 0.8 2.1 ± 0.4 0.4 
5 34 28.5 ± 4.6 5.6 ± 0.6 8.3 ± 1.1 0.3 
 
 
On the basis of the SAR data, incorporation of both the butenolide moiety and 
a benzyl-protected alcohol in place of the alkyl side chain indicated that the benzyl 
analogue 37 (entry 4) had similar activity to 32. Removal of the benzyl group to 
reveal the free hydroxyl analogue 34 (entry 5), was found to diminish activity and was 
9 times less active than 32, with EC50 values of 28.5 ± 4.6 and 3.2 ± 0.1 µM, 
respectively. This may indicate that a non-hydrophilic arm on the opposite side of the 
butenolide moiety is required for maximum protein/analogue/lipid interaction. 
 
 
Lipophilic efficiency 
A theoretical comparison of the triazole analogues molecular properties was 
conducted in an effort to highlight the lipophilicity of these compounds and provide 
an indication as to whether they would be suitable drug candidates. As outlined in 
Table 3, the data indicated that our lead compound alcohol 23 (entry 1) displayed a 
suitable log P of 5.163, had a molecular weight less than 500 and had a suitable 
number of hydrogen bond donors and acceptors, adhering to Lipinski’s rule of 5. 
Introduction of the butenolide moiety on one end of the THP ring system and an alkyl 
side chain on the opposite side in analogue 32 (entry 2), led to an increased log P 
value of 9. Exchange of the hydrophobic alkyl side chain with either a benzyl group 
(37, entry 4) or a free hydroxyl group (34, entry 3) decreased log P values while 
increasing the potential for hydrogen bond donation. Chamuvarinin itself (6, entry 5) 
displayed a high log P value of 9 in line with the observed ability of acetogenin 
family members to cross the blood-brain barrier[23] The lipophilic efficiency (LipE) is 
a combination of the calculated lipophilicity (clogP) and the potency (pEC50) of 
analogues to estimate the drug-likeness (LipE >5) of compounds. As highlighted in 
Table 3, triazoles 23, 32, 34, 37 and chamuvarinin 6 exhibited values ranging from 
+0.6 to -3.7, which are lower than the proposed optimal LipE of typical drug 
candidates. The calculated LipE values (Table 3) for triazoles 23, 32, 34, 37 and 
chamuvarinin 6 fall in the range +0.6 to -3.7, which although below the optimal value 
are in line with values often displayed by natural products and their derivatives.[24]  
Furthermore the LipE values of our designed triazole analogues are comparable with 
bioactive compounds that cross the blood brain barrier[23,24] which when coupled with 
their toxicity towards T. brucei provides the exciting prospect of developing an 
effective dual pronged treatment for Stage 1 and 2 HAT if selectivity profiles can be 
further improved. 
 
[INSERT TABLE 3] 
Table 3. Theoretical data of molecular properties for triazole analogues 6, 23, 32, 34 
and 37. 
Entry Compound T. brucei (BSF)   
EC50 (µM) 
pEC50 clog P LipE MW H bond 
donors 
H bond 
acceptors 
1 23 1.8 ± 0.1 5.75 5.163 0.59 407.6 1 6 
2 32 3.2 ± 0.1 5.49 9.056 -3.57 571.8 0 7 
3 34 28.5 ± 4.6 4.55 7.336 -2.79 559.8 1 8 
4 37 5.2 ± 0.3 5.29 8.935 -3.65 649.9 1 8 
5 6 1.4 ± 0.1 5.86 9.208 -3.35 604.9 1 6 
 
 
Molecular modelling 
Our initial rationale for the design and synthesis of simplified triazole 
analogues was based on the molecular modelling of the central tricyclic core of 
chamuvarinin (6), as outlined in Figure 3a, indicating that 6 adopts a “U-shape” 
conformation.[25] We hypothesized that a 5-membered heterocyclic spacer (Figures 3b 
and 3c) would act as an effective spatial mimic for the central THF core of 6 and thus 
retain potent biological activity. Modelling highlights that the lowest energy 
conformation of the syn-syn bis-THP rings acts a better mimic of this ‘U-shaped’ 
conformation than the corresponding anti-anti and this would appear to be broadly 
born out by the biological results.[25] The encouraging trypanocidal activity of the 
triazole compounds discussed in this paper has now formed the basis of further design 
iterations and lead structure optimization. The evolving structure-activity-relationship 
will be enabled by further cycles of iterative design towards the development of more 
potent and selective trypanocidal compounds. 
 
[INSERT FIGURE 3] 
 
Conclusion 
 
A focused library of 1,4-triazole-based acetogenin analogues have been synthesized 
and have demonstrated low micromolar trypanocidal activities against both 
bloodstream and procyclic forms of T. brucei. Analogue 23 has displayed comparable 
levels of T. brucei inhibition to that of natural product chamuvarinin (6), EC50 values 
of 1.8 ± 0.1 and 1.4 ± 0.1 µM, respectively demonstrating that this series of triazole 
analogues are potential lead compounds for the development of an effective 
therapeutic agent for HAT. The acetogenins have long been established as 
mitochondrial Complex I inhibitors within mammalian cells, therefore, it is postulated 
that the analogues are targeting a protein within the mitochondrion of the parasite. 
The specific protein target and mode of action for parasite inhibition is currently 
undetermined for these analogues. However, analogues 31 and 32 clearly highlight 
that spatial orientation of the butenolide side chain impacts heavily on T. brucei 
inhibition. Current focus is to establish whether the analogues are disrupting 
mitochondrial functions through the incorporation of fluorescent and affinity tags to 
lead triazole compounds in order to isolate specific proteins of interest, allowing them 
to be genetically and chemically validated. 
Experimental Section 
See supporting information for full experimental details 
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Figure Captions 
 
Caption for Figure 1 
Figure 1. Current drugs for treatment of Human African trypanosomiasis. 
 
Caption for Figure 2 
Figure 2. Rationale for simplified analogue design. 
 
Caption for Scheme 1 
Scheme 1. Synthesis of azides 11a-c, 12 and 13 and alkynes 16a-b and 17a-b: a) 
CH2CHCH2CH2MgBr, CuI, THF, -40 °C → RT; b) mCPBA, CH2Cl2, 0 °C → RT; 
then (±)-CSA (20 mol%), RT; c) PPh3, iPr2NEt, DIAD, DPPA, 0 ºC → RT; d) 
(COCl)2, DMSO, CH2Cl2, Et3N, -78 °C → RT; e) dimethyl diazo-2-
oxopropylphosphonate, K2CO3, MeOH, RT; f) CBr4, PPh3, CH2Cl2, 0 ºC then -78 ºC; 
g) n-BuLi, THF, -78 ºC. mCPBA = 3-chloroperbenzoic acid, (±)-CSA = (±)-
camphorsulfonic acid, DIAD = diisopropyl azodicarboxylate, DPPA = diphenyl 
phosphoryl azide, DMSO = dimethyl sulfoxide 
 
Caption for Scheme 2 
Scheme 2. Synthesis of triazole analogues 18a-d, 19a-b, 20a-b, 21a-b and 22: a) 
CuSO45H2O, Na ascorbate, H2O, t-BuOH, RT. 
 
Caption for Scheme 3 
Scheme 3. Synthesis of alcohols 23-28: a) 20% Pd(OH)2/C, H2 (1 atm), EtOH, RT. 
 
Caption for Scheme 4 
Scheme 4. Synthesis of triazoles 31 and 32: a) 1H-mercaptophenyltetrazole, PPh3, 
DIAD, 0 °C; b) (NH4)6Mo7O24•4H2O, H2O2, EtOH, 0 °C  RT; c) NaHMDS, THF, -
78 °C; then 30, THF -78  -20 °C; d) TsNHNH2, NaOAc, DME, H2O, 100 °C. PT = 
phenyl tetrazole, NaHMDS = sodium hexamethyldisilylazide, DME = 
dimethoxyethane. 
 
 
 
Caption for Scheme 5 
Scheme 5. Synthesis of advanced alcohol 34: a) TBAF, THF, 0 ºC  RT; b) 1H-
mercaptophenyltetrazole, PPh3, DIAD, 0 °C; c) (NH4)6Mo7O24•4H2O, H2O2, EtOH, 0 
°C  RT; d) NaHMDS, THF, -78 °C; then 30, THF -78  -20 °C; e) TsNHNH2, 
NaOAc, DME, H2O, 100 °C; f) BCl3•SMe2, CH2Cl2, -78 °C  RT; g) 20% 
Pd(OH)2/C, H2 (1 atm), EtOH, RT.  TBAF = tetrabutylammonium fluoride. 
 
Caption for Table 1 
Table 1. SAR data for ethyl analogues 20a, 21a, 18a, 19a, benzyl analogues 20b, 21b, 
18b, 35, 19b, 22 and alcohol analogues 23-27, 38; selectivity index refers to BSF 
parasitic inhibition versus mammalian HeLa inhibition; chamuvarinin (6, T. brucei 
(BSF) EC50 = 1.4 ± 0.1 µM; T. brucei (Pro) EC50 = 1.9 ± 0.1 µM; HeLa EC50 = 2.9 ± 
0.7 µM taken from ref. 9). 
 
Caption for Table 2 
Table 2. Biological profiles for analogues 23, 31-32, 34 and 37, selectivity index 
refers to BSF parasitic inhibition versus mammalian HeLa inhibition. 
 
Caption for Table 3 
Table 3. Theoretical data of molecular properties for triazole analogues 6, 23, 32, 34 
and 37. 
 
Caption for Figure 3 
Figure 3. Molecular modelling of the lowest energy conformations for a) 
chamuvarinin framework; b) syn-syn triazole core; and c) anti-anti triazole core. 
 
  
Text for the Table of Contents 
A series of novel bis-tetrahydropyran 1,4-triazole analogues based on the acetogenin 
framework display low micromolar trypanocidal activities towards both bloodstream 
and insect forms of Trypanosoma brucei, the causative agent of African sleeping 
sickness.  
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Table 1: 
Entry Analogue R group EC50 (µM) Selectivity 
Index 
Entry Analogue R group EC50 (µM) Selectivity 
Index 
T. 
brucei 
(BSF)  
T. 
brucei 
(Pro)  
HeLa T. 
brucei 
(BSF) 
T. 
brucei 
(Pro)  
HeLa 
 
1  20a 
R = Et 
24.6 ± 
1.4 
65.0 ± 
3.1 
33.0 ± 
2.4 
1.3 9  23 
R1 = Et 
R2 = OH 
1.8 ± 
0.1 
0.8 ± 
0.11 
7.0 ± 
1.0 
3.9 
2 20b 
R = OBn 
467.2 ± 
40.3 
236.6 ± 
23.8 
>1000 >2 10 35 
R1 = OH 
R2 = OBn 
16.2 ± 
0.9 
19.4 ± 
0.5 
>100 >6 
3 25 
R = OH 
223.2 ± 
21.8 
87.9 ± 
4.5 
415.8 ± 
35.3 
1.9 11 38 
R1 = R2 = OH 
157.8 ± 
13.2 
99.0 ± 
2.5 
>250 >1.5 
  
      
 
     
4  21a 
R = Et 
37.2 ± 
6.6 
81.5 ± 
4.5 
>500 >6 12  19a 
R = Et 
7.6 ± 
0.3 
1.1 ± 
0.1 
166.6 
± 18.0 
21.9 
5 21b 
R = OBn 
3.10 ± 
0.1 
48.7 ± 
3.6 
71.4 ± 
4.1 
23 13 19b 
R = OBn 
10.1 ± 
0.4 
72.3 ± 
5.3 
76.0 ± 
3.0 
7.5 
6 26 
R = OH 
72.4 ± 
3.9 
68.3 ± 
7.2 
59.7 ± 
2.5 
0.8 14 24 
R = OH 
17.5 ± 
1.0 
25.4 ± 
1.3 
26.9 ± 
1.1 
1.5 
  
      
 
     
7 
 
18a 
R1 = R2 = Et 
48.7 ± 
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4.6 
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R1 = Et 
R2 = OBn 
8.70 ± 
0.5 
15.6 ± 
0.3 
45.5 ± 
2.5 
5.3 16 27 
R = OH 
19.2 ± 
1.1 
42.9 ± 
2.4 
101.0 
± 10.4 
5.3 
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